Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines

NCT01367158 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

440

Enrollment

INDUSTRY

Sponsor class

Conditions

Meningococcal Disease
Meningococcal Meningitis

Interventions

BIOLOGICAL: Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine
BIOLOGICAL: Meningococcal (group B) multicomponent recombinant adsorbed vaccine
BIOLOGICAL: Tdap

Sponsor

Novartis Vaccines